JP2019014758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019014758A5 JP2019014758A5 JP2018206547A JP2018206547A JP2019014758A5 JP 2019014758 A5 JP2019014758 A5 JP 2019014758A5 JP 2018206547 A JP2018206547 A JP 2018206547A JP 2018206547 A JP2018206547 A JP 2018206547A JP 2019014758 A5 JP2019014758 A5 JP 2019014758A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- optionally substituted
- cancer
- dutpase
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(*C1)C1(C*1C(CC**)=C*=*1)O Chemical compound CC(*C1)C1(C*1C(CC**)=C*=*1)O 0.000 description 4
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749791P | 2013-01-07 | 2013-01-07 | |
| US61/749,791 | 2013-01-07 | ||
| US201361874643P | 2013-09-06 | 2013-09-06 | |
| US61/874,643 | 2013-09-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551794A Division JP6450323B2 (ja) | 2013-01-07 | 2014-01-03 | デオキシウリジントリホスファターゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019014758A JP2019014758A (ja) | 2019-01-31 |
| JP2019014758A5 true JP2019014758A5 (enExample) | 2019-05-09 |
| JP6660993B2 JP6660993B2 (ja) | 2020-03-11 |
Family
ID=50030487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551794A Active JP6450323B2 (ja) | 2013-01-07 | 2014-01-03 | デオキシウリジントリホスファターゼ阻害剤 |
| JP2018206547A Active JP6660993B2 (ja) | 2013-01-07 | 2018-11-01 | デオキシウリジントリホスファターゼ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551794A Active JP6450323B2 (ja) | 2013-01-07 | 2014-01-03 | デオキシウリジントリホスファターゼ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9809571B2 (enExample) |
| EP (1) | EP2941423B1 (enExample) |
| JP (2) | JP6450323B2 (enExample) |
| CN (1) | CN105189478B (enExample) |
| CA (1) | CA2914178C (enExample) |
| IL (1) | IL239827B (enExample) |
| WO (1) | WO2014107622A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014107622A1 (en) | 2013-01-07 | 2014-07-10 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2015103489A1 (en) | 2014-01-03 | 2015-07-09 | University Of Southern California | Heteroatom containing deoxyuridine triphosphatase inhibitors |
| DK3319939T3 (da) * | 2015-07-08 | 2025-02-24 | Cv6 Therapeutics Ni Ltd | Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| CN109153644B (zh) | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| WO2018098209A1 (en) * | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| EP3571193B1 (en) | 2017-01-23 | 2021-12-01 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3820532A4 (en) | 2018-07-11 | 2022-04-06 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS |
| MX2021004647A (es) | 2018-10-22 | 2021-08-16 | Novartis Ag | Formas cristalinas de moduladores de los canales de potasio. |
| BR112022026247A2 (pt) | 2020-06-26 | 2023-01-17 | Cv6 Therapeutics Ni Ltd | Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer |
| WO2022197978A1 (en) * | 2021-03-17 | 2022-09-22 | President And Fellows Of Harvard College | Compositions and methods for modulating mitochondrial function and biogenesis |
| AU2022300033A1 (en) * | 2021-06-21 | 2024-01-18 | Beone Medicines I Gmbh | (r) -glutarimide crbn ligands and methods of use |
| WO2026156174A1 (en) | 2025-01-16 | 2026-07-23 | Cv6 Therapeutics (Ni) Limited | Parp inhibitor combination therapy with deoxyuridine triphosphatase inhibitors |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4829785B1 (enExample) | 1970-03-26 | 1973-09-13 | ||
| BE787766A (fr) * | 1971-08-21 | 1973-02-19 | Merck Patent Gmbh | Imides d'acide glutarique et leur procede de preparation |
| US4063019A (en) | 1976-03-30 | 1977-12-13 | E. R. Squibb & Sons, Inc. | [[[(2,4-Dioxo-1-imidazolidinyl)amino]carbonyl]amino]-acetylcephalosporin derivatives |
| US4304715A (en) | 1979-06-08 | 1981-12-08 | Derek Hudson | Enkephalin analogues |
| DE3027596A1 (de) | 1980-07-21 | 1982-02-18 | Bayer Ag, 5090 Leverkusen | Triazolidin-3,5-dion-oxyalkylverbindungen und verfahren zu ihrer herstellung |
| JPS5839672A (ja) | 1981-09-03 | 1983-03-08 | Chugai Pharmaceut Co Ltd | ウラシル誘導体 |
| JPS60243017A (ja) | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| JPH0674251B2 (ja) | 1986-02-07 | 1994-09-21 | 全薬工業株式▲会▼社 | ビス−ジオキソピペラジン誘導体 |
| JPS63101361A (ja) * | 1986-09-08 | 1988-05-06 | ブリティッシュ・テクノロジー・グループ・リミテッド | ジオキソピペリジン誘導体を含有する不安解消組成物 |
| FR2644786B1 (fr) | 1989-03-21 | 1993-12-31 | Adir Cie | Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5599796A (en) | 1993-12-02 | 1997-02-04 | Emory University | Treatment of urogenital cancer with boron neutron capture therapy |
| CA2200964A1 (en) | 1994-11-24 | 1996-05-30 | Takeda Chemical Industries, Ltd. | Alpha-ketoamide derivatives as cathepsin l inhibitor |
| US5962246A (en) | 1996-03-29 | 1999-10-05 | The University Of Medicine And Dentistry Of New Jersey | dUTPase, its isoforms, and diagnostic and other uses |
| JPH09286786A (ja) | 1996-04-18 | 1997-11-04 | Nippon Paper Ind Co Ltd | ピリミジン誘導体及びその抗腫瘍剤としての用途 |
| DE19756212A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| WO1999031066A1 (en) | 1997-12-18 | 1999-06-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyridones as src family sh2 domain inhibitors |
| EP1165500A1 (en) | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
| MXPA03008180A (es) | 2001-03-15 | 2003-12-12 | Astrazeneca Ab | Inhibidores de metaloproteinasa. |
| JP2002284686A (ja) | 2001-03-28 | 2002-10-03 | Sankyo Co Ltd | スルホンアミド化合物を含有する医薬組成物 |
| WO2002083651A2 (en) | 2001-04-11 | 2002-10-24 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| AU2003249812A1 (en) | 2002-07-18 | 2004-02-09 | Queen's University At Kingston | Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents |
| AU2003256655A1 (en) | 2002-07-25 | 2004-02-16 | Merck And Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| GB0400290D0 (en) | 2004-01-08 | 2004-02-11 | Medivir Ab | dUTPase inhibitors |
| BRPI0607239A2 (pt) | 2005-01-25 | 2009-08-25 | Celgene Corp | usos de uma quantidade terapeuticamente ou profilaticamente eficaz de 4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol-1,3-d iona, de (3r)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, e de (3s)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, ou um sal ou solvato farmaceuticamente aceitável das mesmas, composição farmacêutica, e, forma de dosagem unitária simples |
| WO2006135763A2 (en) | 2005-06-09 | 2006-12-21 | The Johns Hopkins University | Inhibitors of dna repair enzymes and methods of use thereof |
| WO2008016522A2 (en) | 2006-07-24 | 2008-02-07 | Gilead Sciences, Inc. | Hiv reverse transcriptase inhibitors |
| EP1939186A1 (en) | 2006-12-22 | 2008-07-02 | Sulfidris S.r.l. | 5-Fluorouracil derivatives and their use for the treatment of cancer |
| BRPI0820669A2 (pt) | 2007-12-10 | 2020-08-04 | Novartis Ag | compostos orgânicos |
| CN102056905B (zh) | 2008-06-03 | 2014-03-26 | 大鹏药品工业株式会社 | 具有人脱氧尿苷三磷酸酶抑制活性的尿嘧啶化合物或其盐 |
| US20110212467A1 (en) | 2008-08-27 | 2011-09-01 | University Of Southern California | INHIBITORS OF dUTPase |
| JP2011231015A (ja) * | 2008-08-29 | 2011-11-17 | Taiho Yakuhin Kogyo Kk | 含窒素複素環を有する新規ウラシル化合物又はその塩 |
| US20110306551A1 (en) | 2009-02-19 | 2011-12-15 | Novo Nordisk A/S | Modification of Factor VIII |
| US8912329B2 (en) | 2009-06-25 | 2014-12-16 | BioVersys AG | Composition for treatment of tuberculosis |
| JP2013032293A (ja) * | 2009-11-30 | 2013-02-14 | Taiho Yakuhin Kogyo Kk | ヒトｄＵＴＰａｓｅ阻害活性を有する５−フルオロウラシル化合物又はその塩 |
| JP5336606B2 (ja) | 2009-11-30 | 2013-11-06 | 大鵬薬品工業株式会社 | 抗腫瘍効果増強剤 |
| JP2013047189A (ja) | 2009-12-25 | 2013-03-07 | Kyorin Pharmaceutical Co Ltd | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 |
| GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| WO2013012848A1 (en) | 2011-07-18 | 2013-01-24 | Merck Patent Gmbh | Benzamides |
| AP2014007637A0 (en) | 2011-11-15 | 2014-05-31 | Takeda Pharmaceutical | Dihydroxy aromatic heterocyclic compound |
| WO2014107622A1 (en) | 2013-01-07 | 2014-07-10 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2015103489A1 (en) | 2014-01-03 | 2015-07-09 | University Of Southern California | Heteroatom containing deoxyuridine triphosphatase inhibitors |
| WO2015142001A2 (ko) | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| US20180110780A1 (en) | 2015-04-30 | 2018-04-26 | Taiho Pharmaceutical Co., Ltd. | Agent for alleviating side effect of antitumor drug |
| SG11201708613SA (en) | 2015-05-01 | 2017-11-29 | Taiho Pharmaceutical Co Ltd | Novel crystal of uracil compound |
| DK3319939T3 (da) | 2015-07-08 | 2025-02-24 | Cv6 Therapeutics Ni Ltd | Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer |
| US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
-
2014
- 2014-01-03 WO PCT/US2014/010247 patent/WO2014107622A1/en not_active Ceased
- 2014-01-03 CA CA2914178A patent/CA2914178C/en active Active
- 2014-01-03 JP JP2015551794A patent/JP6450323B2/ja active Active
- 2014-01-03 US US14/759,386 patent/US9809571B2/en not_active Expired - Fee Related
- 2014-01-03 CN CN201480012364.XA patent/CN105189478B/zh active Active
- 2014-01-03 EP EP14702109.1A patent/EP2941423B1/en active Active
-
2015
- 2015-07-07 IL IL239827A patent/IL239827B/en active IP Right Grant
-
2017
- 2017-09-21 US US15/711,680 patent/US10227326B2/en active Active
-
2018
- 2018-11-01 JP JP2018206547A patent/JP6660993B2/ja active Active
-
2019
- 2019-03-08 US US16/297,221 patent/US10889563B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521431048B1 (ar) | مركبات بيروليدين | |
| US10179787B2 (en) | Chemokine receptor modulators and uses thereof | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| JP2023533938A5 (enExample) | ||
| JP2020505405A5 (enExample) | ||
| JP2017502967A5 (enExample) | ||
| JP2016505621A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| MX2023009857A (es) | Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos. | |
| JP2011509949A5 (enExample) | ||
| JP2013502430A5 (enExample) | ||
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| JP2017523997A5 (enExample) | ||
| JP2017537882A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| MXPA05010712A (es) | Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias. | |
| JP2017508782A5 (enExample) | ||
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2017511378A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2013538213A5 (enExample) | ||
| JP2018507257A5 (enExample) | ||
| MX2025004221A (es) | Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos |